Perturbations to cell signaling and receptor trafficking in the context of EGFR mutation.
The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that drives signaling processes involved in proliferation, survival, and migration in cells and tissues throughout the body. EGFR mutation and over-expression are observed in numerous human malignancies. Mutations that lead to the constitutive activation of EGFR in lung and brain cancers are of special interest to our lab, in part because these mutations alter the important coupling between receptor trafficking and downstream signaling in ways that ultimately influence cancer cell fates, including response to therapy. In cancer cells expressing these EGFR mutants, our lab is particularly interested in the functions of two downstream regulators of EGFR-mediated signaling, the protein tyrosine phosphatase SHP2 and the EGFR feedback regulator Sprouty2.